WO2007035028A1 - Novel resinate complex of s-clopidogrel and production method thereof - Google Patents
Novel resinate complex of s-clopidogrel and production method thereof Download PDFInfo
- Publication number
- WO2007035028A1 WO2007035028A1 PCT/KR2006/003346 KR2006003346W WO2007035028A1 WO 2007035028 A1 WO2007035028 A1 WO 2007035028A1 KR 2006003346 W KR2006003346 W KR 2006003346W WO 2007035028 A1 WO2007035028 A1 WO 2007035028A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- clopidogrel
- water
- complex
- isomer
- exchange resin
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- 229960003009 clopidogrel Drugs 0.000 title description 47
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 title description 44
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims abstract description 124
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000007787 solid Substances 0.000 claims abstract description 32
- 239000003729 cation exchange resin Substances 0.000 claims abstract description 29
- 125000000542 sulfonic acid group Chemical group 0.000 claims abstract description 18
- 229920000642 polymer Polymers 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 14
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 10
- 239000003513 alkali Substances 0.000 claims description 6
- 229910052783 alkali metal Inorganic materials 0.000 claims description 6
- 150000001340 alkali metals Chemical class 0.000 claims description 6
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 229940023913 cation exchange resins Drugs 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 16
- 235000019658 bitter taste Nutrition 0.000 abstract description 10
- 230000007794 irritation Effects 0.000 abstract description 10
- 239000000126 substance Substances 0.000 abstract description 9
- 230000003287 optical effect Effects 0.000 abstract description 7
- 235000019614 sour taste Nutrition 0.000 abstract description 6
- 239000000243 solution Substances 0.000 description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 42
- 239000012458 free base Substances 0.000 description 33
- 239000000203 mixture Substances 0.000 description 24
- 239000003456 ion exchange resin Substances 0.000 description 23
- 229920003303 ion-exchange polymer Polymers 0.000 description 23
- 235000019640 taste Nutrition 0.000 description 16
- -1 ester compound Chemical class 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 238000001556 precipitation Methods 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 11
- 239000011347 resin Substances 0.000 description 11
- 229920005989 resin Polymers 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 239000003960 organic solvent Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 230000000873 masking effect Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 229920001429 chelating resin Polymers 0.000 description 6
- 239000007884 disintegrant Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 6
- 239000012730 sustained-release form Substances 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000013590 bulk material Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 5
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229950010477 clopidogrel hydrogen sulphate Drugs 0.000 description 4
- 229940049654 glyceryl behenate Drugs 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- FDEODCTUSIWGLK-UHFFFAOYSA-N hydrogen sulfate;hydron;methyl 2-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)acetate Chemical compound OS(O)(=O)=O.C1CC=2SC=CC=2CN1C(C(=O)OC)C1=CC=CC=C1Cl FDEODCTUSIWGLK-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229940079832 sodium starch glycolate Drugs 0.000 description 4
- 239000008109 sodium starch glycolate Substances 0.000 description 4
- 229920003109 sodium starch glycolate Polymers 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229920003169 water-soluble polymer Polymers 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001342 alkaline earth metals Chemical class 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960004132 diethyl ether Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000008043 acidic salts Chemical class 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000007769 metal material Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 231100000017 mucous membrane irritation Toxicity 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- BKRHEVJTTWAYFJ-UHFFFAOYSA-N CC(C(C)N)c1ccccc1 Chemical compound CC(C(C)N)c1ccccc1 BKRHEVJTTWAYFJ-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 229960005164 acesulfame Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- HHKWQFVQMZJXNC-UHFFFAOYSA-L calcium;2-phenylethenesulfonate Chemical compound [Ca+2].[O-]S(=O)(=O)C=CC1=CC=CC=C1.[O-]S(=O)(=O)C=CC1=CC=CC=C1 HHKWQFVQMZJXNC-UHFFFAOYSA-L 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000002242 deionisation method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- QIFCIFLDTQJGHQ-UHFFFAOYSA-M potassium;2-phenylethenesulfonate Chemical compound [K+].[O-]S(=O)(=O)C=CC1=CC=CC=C1 QIFCIFLDTQJGHQ-UHFFFAOYSA-M 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003306 quinoline derived antiinfective agent Substances 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- MNCGMVDMOKPCSQ-UHFFFAOYSA-M sodium;2-phenylethenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C=CC1=CC=CC=C1 MNCGMVDMOKPCSQ-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000009662 stress testing Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F12/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
- C08F12/02—Monomers containing only one unsaturated aliphatic radical
- C08F12/04—Monomers containing only one unsaturated aliphatic radical containing one ring
- C08F12/14—Monomers containing only one unsaturated aliphatic radical containing one ring substituted by hetero atoms or groups containing heteroatoms
- C08F12/30—Sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F12/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
- C08F12/34—Monomers containing two or more unsaturated aliphatic radicals
- C08F12/36—Divinylbenzene
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
- C08J5/20—Manufacture of shaped structures of ion-exchange resins
Definitions
- the present invention is a novel resinate complex of (+)-clopidogrel optical isomer, wherein the (+)-clopidogrel isomer is bounded to a water-soluble cation exchange resin having sulfonic acid groups.
- Clopidogrel has shown to have activity with inhibitory properties towards platelet aggregation, and is useful for the treatment and prevention of thromboembolism such as stroke or myocardial infarction. Dextrorotary clopidogrel or racemate exhibits activity on platelet aggregation, whereas the levorotatory isomer is less active and poorly tolerated. [4] [5] Clopidogrel (free base) is a semi-solid (oily) form with high- viscosity flowability, affecting the storage or handling process. Its low solubility to water makes it difficult to industrially develop a pharmaceutical product.
- the Korean Patent Publication No. 1987-1270 disclosed a variety of acidic salts (hydrochloric acid, sulfuric acid) which aims to crystallize an oily clopidogrel racemate.
- the Korean Patent Publication No. 1996-3615 described a method of crystallizing an oily (+) -clopidogrel isomer using some water-soluble salts (sulfate, tau- rocholate, and bromate) that serves to easily achieve the crystallization of active clopidogrel with no hygroscopicity.
- WO 04/106344, WO 05/016931, U.S. Patent No. 4,847,265, U.S. Patent Application No. 2004/0132765 and U.S. Patent Application No. 2005/0059696 disclosed the solid forms of monomolecular clopidogrel addition acidic salts as a single molecule.
- the Korean Patent Unexamined Publication No. 2005-8692A disclosed clopidogrel sulfonate.
- Clopidogrel (free base) has a crystalline or amorphous solid form in the concentrated inorganic or organic acid. If the use of monomolecular acidic materials employed for making the clopidogrel addition salts, ester in clopidogrel (free base) is hydrolyzed into carboxylic acid and methanol (An ester compound is decomposed by an acid, thus generating acid and alcohol). The carboxylic acid compound thus formed is an impurity of clopidogrel.
- the monomolecular acidic materials used for preparing clopidogrel addition salts affects the stability of ester in the molecule, thus making its structure unstable before the drug is delivered to the body and affecting the safety and efficacy of clopidogrel in the gastrointestinal tract.
- WO 99/30690, WO 04/103349 and U.S. Patent No. 6,800,668 disclosed the use of an ion exchange resin as a sustained release agent or stabilizer.
- U.S. Patent No. 3,608,063 disclosed a process for preparing polymer particles that may be released from latex in water.
- U.S. Patent No. 4,369,175 disclosed a process for manufacturing sustained release vicamine resinate directly from the resinate of alkali metal or alkaline earth metal salt.
- U.S. Patent No. 4,788,055 disclosed a resinate sustained release dextromethorphan composition.
- U.S. Patent Nos. 3,138,525, 4,762,709 and 4,996,047 disclosed a process for preparing a sustained release agent, wherein polymer particles are prepared with or without an additive to support the incomplete sustained release property of an agent- resin complex, followed by coating the complex with a water-permeable diffusion barrier (water-soluble or water- insoluble).
- U.S. Patent No. 5,980,882 disclosed a pharmaceutical composition comprising a drug-resin complex and a chelating agent (EDTA) for improving the stability of a pharmaceutical composition.
- EDTA chelating agent
- U.S. Patent Nos. 4,459,278 and 5,643,560 disclosed the use of ion exchange resins to modify drug release rate, drug absorption and reduce side effects, while sustaining a plasma concentration.
- clopidogrel is a drug which is unpleasant to take orally in the mouth and/or gastrointestinal tract due to a strong irritation, bitter and sour taste.
- a composition comprising the drug-resin complexes of the present invention surprisingly has a taste-masking capabilities (strong irritation, bitterness and obnoxious taste) against (+)-clopidogrel sulfate.
- the Korean Patent Unexamined Publication No. 2004-66917 disclosed the use of a viscosity enhancer in clopidogrel hydrogen sulfate for a pleasant tasting with good mouth-feel. This taste masking has been limited with little improvement of bitter and obnoxious taste.
- U.S. Patent No. 3,901,248 disclosed a chewable smoking substitute composition that comprises a chewing gum base and nicotine in combination with certain saliva- insoluble cation exchange resins.
- U.S. Patent Nos. 5,032,393 and 5,219,563 disclosed a chewing gum or sucking agent by adsorption of ranitidine onto the ion exchange resin particles to form the drug-resin complex.
- U.S. Patent No. 6,514,492 disclosed a pharmaceutical suspension composition comprising a quinolone antibiotic, one or more expients and an ion exchange resin.
- (+)-clopidogrel isomer bounded with water-soluble cation exchange resin had better stability in its chemical structure, taste-masking capabilities (strong irritation, bitterness and obnoxious taste) against(+)-clopidogrel sulfate and a variety of dosage forms, such as solid preparation requiring no drink of water and liquid preparation (syrup).
- a further object of the present invention is to provide a novel clopidogrel bulk material with a combination of hygroscopicity-free property and excellent flowability to a powder form, and as a result, such bulk material can be easily formulated into particular dosage forms.
- Another object of the present invention is to provide a novel clopidogrel bulk material that may be formulated as a solid preparation with no drink of water or a liquid preparation (e.g., syrup) by taste-masking capabilities (strong irritation, bitterness and obnoxious taste) against hydrogen sulfate of (+)-clopidogrel isomer.
- Another object of the present invention is to provide a process for manufacturing a novel clopidogrel bulk material.
- the present invention is to provide a clopidogrel-resinate complex and its manufacturing method, wherein an oily (+) -clopidogrel isomer (free base) is bounded to a water-soluble cation exchange resin having sulfonic acid groups and a molecular weight range of 5,000 to 1,000,000.
- the clopidogrel-resinate complex is characterized by the fact that (1) its crystal structure is stable, and (2) it provide excellent flowability to a powder form.
- Clopidogrel of the present invention is a generic name for methyl(+)-(S)-(2-chlorophenyl)(6,7-dihydro-4H-thieno[3,2-c]pyridine-5-yl)acetate as a dextrorotary optical isomer.
- polymers used in the clopidogrel-resinate complex of the present invention represent styrene sulfonate polymer or divinylbenzene styrene sulfonate copolymer.
- the water-soluble cation exchange resin having sulfonic acid groups of the present invention is characterized by an ion exchange capacity.
- such resin has sulfonic acid-derived anionic groups that can be reacted with amine groups of the drug.
- the molecular weight of a water-soluble polymer is in the range from 5,000 to 1,000,000. More preferably, the molecular weight of a water-soluble polymer is in the range from 10,000 to 500,000. If the molecular weight of a water-soluble polymer exceeds 1,000,000, its solubility loss may occur.
- the water- insoluble cation exchange resin having sulfonic acid groups has a limit in binding clopidogrel to resin particles, requiring excess amount of ion exchange resins. The final solid product does not contribute to the structural stability of (+)-clopidogrel isomer.
- a water-soluble polymer used for forming the clopidogrel-resinate complex may be selected from a cation exchange resin forming as styrene, or styrene with divinyl benzene, as shown in the following formula 1 or 2.
- [M + ] is a substituted acidic sufonic acid in the benzene structure but is further replaced by hydrogen atom or acid derivatives having a variety of substituted alkali metal or alkali earth metal.
- the polymer is pretreated with a strong acid to recover an ionic binding capacity and washed with water or organic solvent to form a complex of clopidogrel (free base) with resin.
- the ion exchange resins suitable for use in the present invention may be one or more polymers selected from the group consisting of water-soluble styrene sulfonate polymer and divinyl benzene styrene sulfonate copolymer.
- the ion exchange resins bounded to alkali metal or alkaline earth metal e.g., sodium styrene sulfonate polymer, potassium styrene sulfonate polymer, calcium styrene sulfonate polymer, sodium divinyl benzene styrene sulfonate copolymer, potassium divinyl benzene styrene sulfonate copolymer and calcium divinyl benzene styrene sulfonate copolymer) do not deviate the scope of the present invention.
- alkali metal or alkaline earth metal e.g., sodium styrene sulfonate polymer, potassium styrene sulfonate polymer, calcium styrene sulfonate polymer, sodium divinyl benzene styrene sulfonate copolymer, potassium
- the present invention provides an oily (+)-clopidogrel isomer (free base) that is a sticky amorphous semi-solid material in transparent, colorless or weakly brown color at room temperature. Its solubility to water is extremely low. Also, the clopidogrel-resinate complex of the present invention is prepared by removing the salts from clopidogrel salts and substituting ion exchange resins.
- the present invention relates to a process for preparing the clopidogrel-resinate complex whose chemical structure is stable until the complex is delivered into a target site of the body from the gastrointestinal tract, while preventing the possible occurrence of impurities.
- the clopidogrel-resinate complex is prepared in an easy, stable manner, and its formulation into a variety of dosage forms is also available on an industrial basis.
- the drug-resinate complex, so formed, is not hygroscopic in the air and provide excellent flowability to the powder form.
- the solid-form complex starts to dissolve or decompose at more than 200 0 C.
- the clopidogrel-resinate complex according to the present invention is a novel drug which contributes to better stability of clopidogrel that is unstable in free base. Its solid or powder form makes it easier for the novel drug-resin complex to be used for a large industrial production.
- the cation exchange resin having sulfonic acid groups according to the present invention serves to deliver clopidogrel only to the gastrointestinal tract by avoiding its absorption in the body, thus ensuring better safety profile.
- the (+)-clopidogrel isomer-resinate complex according to the present invention is obtained as a solid form in aqueous media containing an organic solvent or water.
- An oily (+)-clopidogrel isomer (free base) is homogenously pasted or dissolved in the organic solvent used in the methodology of the present invention.
- solvents include one or more solvents selected from the group consisting of organic solvent and water.
- the preferred solvent may include one or more anhydrous organic solvents.
- More preferred solvents useful in the present invention may include, but are not limited to one or more solvents selected from the group consisting of acetone, methanol, ethanol, diethyl ether, diisopropyl ether, t-butylmethyl ether and hexane.
- a solid form is precipitated such that the solution of a cation exchange resin is added dropwise to the solution of clopidogrel (free base) dissolved in water or organic solvent. More specifically, (+) -clopidogrel isomer is reacted with the cation exchange resin in liquid state. Both solutions or their mixture thereof allow to stand at room temperature. It is preferred to maintain a cooling state for a high yield of the solid- form clopidogrel. For a higher yield of the solid- form clopidogrel the supernatant is removed after precipitation of the solid form, and then the same amount of anhydrous organic solvent as removed amount is added to the solution and allows to stand. The solid precipitate thus formed is washed with an organic solvent and filtered off.
- the organic solvent used for the methodology of the present invention is employed at room temperature or preferably, at a cooling state.
- Alkali materials according to the present invention include alkali metals, alkaline earth metals and amines.
- Alkali materials is one or more selected from alkali metal materials or alkaline earth metal materials (sodium hydroxide, potassium hydroxide, sodium methoxide, potassium methoxide, sodium ethoxide and potassium ethoxide) and amines(ammonia, methylamine, ethylamine, ethanolamine, alginine and histidine), but not limited to the aforementioned alkali materials.
- the clopidogrel-resinate complex according to the present invention is obtained such that (+)-clopidogrel isomer (free base) and cation exchange resin is mixed in a weight ratio of 1:0.1 to 1:10, preferably 1:0.2 to 1:5, and more prefernably 1:0.5 to 1:2.
- the clopidogrel-resinate complex of the present invention provides excellent flowability to its powder form with an angle of repose of about 30°to 40°. Thus its large-scale industrial production with higher yield of solid-form product may be expected.
- a composition comprising the drug-resin complexes of the present invention surprisingly has taste-masking capabilities (strong irritation, bitterness and obnoxious taste) against(+) -clopidogrel sulfate.
- Clopidogrel hydrogen sulfate is a drug which is unpleasant to take orally in the mouth and/or gastrointestinal tract due to a strong irritation, bitterness and sour taste.
- clopidogrel-resinate complex of the present invention has a masking effect against such irritation, bitterness and sour tastes in the mucosa, with very mild sour but pleasant tasting, when taking orally.
- the clopidogrel-resinate complex of the present invention rapidly melts in the mouth without impurities, while the conventional water-insoluble ion exchange resin does not melt in the mouth and impurities remain.
- the clopidogrel-resinate complex of the present invention has been unexpectedly found to address the problem of obnoxious and sour taste, when taking clopidogrel orally.
- the clopidogrel-resinate complex may improve patient compliance, while it requires no drink of water during administration and can be formulated into a liquid form.
- (+)-clopidogrel isomer resinate complex according to the present invention may be formulated into a variety of dosage forms using a pharmaceutically acceptable common technique such as blending, kneading, grinding, sieving, filling, compressing, lyophilization, spray-drying, fluid-bed drying and centrifugal granulation.
- the pharmaceutical composition of the present invention may be formulated using conventional, pharmaceutically acceptable excipients.
- Such conventional, pharmaceutically acceptable excipients include diluents, binders, disintegrants, coloring agents, sweetening agents, flavors, preservatives, lubricants and a mixture thereof.
- Suitable one or more diluents include, but not limited to one or more selected from a group consisting of lactose, dextrose, microcrystalline cellulose and starch, but not limited to the aforementioned the diluents.
- Suitable one or more binders include, but not limited to polyvinyl pyrrolidone, hy- droxypropyl cellulose, hyrdoxypropylmethyl cellulose, hydroxyethyl cellulose, dicalcium phosphate and sodium alginate. [136]
- Suitable one or more disintegrants include, but not limited to croscarmellose sodium, sodium starch glycolate, cross-linked polyvinyl pyrrolidone, starch paste, low- substituted hydroxypropyl cellulose.
- Suitable one or more coloring agents include, but not limited to soluble and tar pigments.
- Suitable one or more sweetening agents include, but not limited to dextrose, sorbitol, mannitol, aspartame, acesulfame and citric acid.
- Suitable one or more flavors include, but not limited to orange flavor powder, grape flavor powder, strawberry flavor powder and blueberry flavor powder.
- Suitable one or more preservatives include, but not limited to benzoic acid, methylparabene, ethylparabene and propylparabene.
- Suitable one or more lubricants include, but not limited to magnesium stearate, talc, hard silicon dioxide and sucrose fatty acid ester.
- the present invention provides a novel resinate complex of
- the present invention provides the novel resinate complex of
- (+)-clopidogrel isomer with better stability in a chemical structure, thus improving its formulation stability.
- the present invention allows an easier formulation of the resinate complex of (+)-clopidogrel isomer into a variety of dosage forms with no additional process, as it removes the hygroscopicity of crystallized clopidogrel and provides excellent flowability to a powder form.
- the present invention provides the novel resinate complex of
- (+) -clopidogrel isomer that requires no drink of water with patient compliance by taste masking of a bitter drug, and its liquid form may be formulated.
- Fig. 1 shows the results of stress testing on the samples produced by Examples 1, 2 and 8, including Comparative examples 1 and 2.
- Example 1 Methyl(+)-(S)-(2-chlorophenyl)(6,7-dihydro-4H-thieno[3,2-c] pyridine-5-yl)acetate-styrene sulfonate polymer complex
- Example 4 Methyl(+)-(S)-(2-chlorophenyl)(6,7-dihydro-4H-thieno[3,2-c] pyridine-5-yl)acetate-styrene sulfonate polymer complex
- Example 7 Methyl(+)-(S)-(2-chlorophenyl)(6,7-dihydro-4H-thieno[3,2-c] pyridine-5-yl)acetate-styrene sulfonate polymer complex
- Example 8 Methyl(+)-(S)-(2-chlorophenyl)(6,7-dihydro-4H-thieno[3,2-c] pyridine-5-yl)acetate-styrene sulfonate polymer complex
- Example 10 Formulation of clopidogrel-styrene sulfonate polymer complex
- (+)-clopidogrel isomer-resinate complex so formed from Example 8, was blended with a mixture containing 2.Og of sodium starch glycolate as a disintegrant, 1.Og of glyceryl behenate as a lubricant, and a proper amount of microcrystalline cellulose such that a total weight may be 35.0g.
- the final product mixture was used to prepare a tablet such that its active ingredient may contain 75 mg of clopidogrel (free base).
- Example 11 Formulation of clopidogrel-styrene sulfonate polymer complex
- Example 12 Formulation of clopidogrel-styrene sulfonate polymer complex
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Manufacturing & Machinery (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006800320268A CN101253179B (en) | 2005-09-21 | 2006-08-24 | Novel resinate complex of S-clopidogrel and production method thereof |
EP06783733A EP1926736A4 (en) | 2005-09-21 | 2006-08-24 | Novel resinate complex of s-clopidogrel and production method thereof |
CA2618187A CA2618187C (en) | 2005-09-21 | 2006-08-24 | Novel resinate complex of s-clopidogrel and production method thereof |
JP2008528932A JP2009507014A (en) | 2005-09-21 | 2006-08-24 | Novel resinate complex of S-clopidogrel and its production method |
AU2006292946A AU2006292946B2 (en) | 2005-09-21 | 2006-08-24 | Novel resinate complex of s-clopidogrel and production method thereof |
US12/065,104 US20080226579A1 (en) | 2005-09-21 | 2006-08-24 | Novel Resinate Complex of S-Clopidogrel and Production Method Thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2005-0087628 | 2005-09-21 | ||
KR20050087628 | 2005-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007035028A1 true WO2007035028A1 (en) | 2007-03-29 |
Family
ID=37889044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2006/003346 WO2007035028A1 (en) | 2005-09-21 | 2006-08-24 | Novel resinate complex of s-clopidogrel and production method thereof |
Country Status (8)
Country | Link |
---|---|
US (1) | US20080226579A1 (en) |
EP (1) | EP1926736A4 (en) |
JP (1) | JP2009507014A (en) |
KR (1) | KR100736024B1 (en) |
CN (1) | CN101253179B (en) |
AU (1) | AU2006292946B2 (en) |
CA (1) | CA2618187C (en) |
WO (1) | WO2007035028A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009120182A2 (en) * | 2007-12-20 | 2009-10-01 | Eastman Chemical Company | Sulfo-polymer powder and sulfo-polymer powder blends with carriers and/or actives |
EP2377520A1 (en) * | 2010-03-24 | 2011-10-19 | Ratiopharm GmbH | Pharmaceutical compound of prasugrel |
CN111060625A (en) * | 2019-12-31 | 2020-04-24 | 北京鑫开元医药科技有限公司 | Detection method of 2- (thiophene-2-yl) ethyl p-toluenesulfonate and isomer thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2015045604A1 (en) * | 2013-09-30 | 2017-03-09 | 富士フイルム株式会社 | Orally disintegrating tablets |
US11555080B2 (en) | 2017-05-01 | 2023-01-17 | Nissan Chemical Corporation | Method for preparing anionic macromolecular compound exhibiting improved water solubility |
KR20230126068A (en) | 2022-02-22 | 2023-08-29 | 인제대학교 산학협력단 | A pharmaceutical composition for the controlled release of drug using cationic-exchange resin |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997029753A1 (en) * | 1996-02-19 | 1997-08-21 | Sanofi | New associations of active principles containing clopidogrel and an antithrombotic agent |
WO2000066130A1 (en) * | 1999-04-30 | 2000-11-09 | Sanofi-Synthelabo | Pharmaceutical composition in unit form containing acetylsalcylic acid and clopidogrel hydrogenosulphate |
EP1087976A1 (en) * | 1998-06-15 | 2001-04-04 | Sanofi-Synthelabo | Polymorphic clopidogrel hydrogenesulphate form |
US20030032618A1 (en) * | 1999-12-01 | 2003-02-13 | John Dixon | Pharmaceutical combinations |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2990332A (en) * | 1958-04-02 | 1961-06-27 | Wallace & Tiernan Inc | Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith |
US3138525A (en) * | 1961-06-16 | 1964-06-23 | Hoffmann La Roche | Castor wax-amprotropine-resin compositions |
US3608063A (en) * | 1969-08-15 | 1971-09-21 | Gilbert S Banker | Molecular drug entrapment process and compositions |
US3901248A (en) * | 1970-07-22 | 1975-08-26 | Leo Ab | Chewable smoking substitute composition |
US3987163A (en) * | 1973-07-27 | 1976-10-19 | Burton, Parsons And Company, Inc. | Polystyrene sulfonate containing opthalmic solutions |
US4369175A (en) * | 1981-07-27 | 1983-01-18 | Ciba-Geigy Corporation | Process for the manufacture of prolonged action vincamine preparations, the vincamine preparations so obtained, and medicaments containing them |
US4459278A (en) * | 1983-03-07 | 1984-07-10 | Clear Lake Development Group | Composition and method of immobilizing emetics and method of treating human beings with emetics |
US4762709A (en) * | 1983-09-16 | 1988-08-09 | Pennwalt Corporation | Liquid prolonged release pharmaceutical formulations containing ionic constituents |
US4788055A (en) * | 1985-12-09 | 1988-11-29 | Ciba-Geigy Corporation | Resinate sustained release dextromethorphan composition |
FR2623810B2 (en) * | 1987-02-17 | 1992-01-24 | Sanofi Sa | ALPHA SALTS- (TETRAHYDRO-4,5,6,7 THIENO (3,2-C) PYRIDYL-5) (2-CHLORO-PHENYL) -THETHYL ACETATE DEXTROGYRE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
US5219563A (en) * | 1988-05-11 | 1993-06-15 | Glaxo Group Limited | Drug adsorbates |
IL90245A (en) * | 1988-05-11 | 1994-04-12 | Glaxo Group Ltd | Resin adsorbate comprising ranitidine together with a synthetic cation exchange resin, its preparation and pharmaceutical compositions containing it |
US4996047A (en) * | 1988-11-02 | 1991-02-26 | Richardson-Vicks, Inc. | Sustained release drug-resin complexes |
SE9103110D0 (en) * | 1991-10-24 | 1991-10-24 | Kabi Pharmacia Ab | NEW DRUG FORMULATION |
US5980882A (en) * | 1997-04-16 | 1999-11-09 | Medeva Pharmaceuticals Manufacturing | Drug-resin complexes stabilized by chelating agents |
US6514492B1 (en) * | 1999-07-14 | 2003-02-04 | Schering-Plough Veterinary Corporation | Taste masking of oral quinolone liquid preparations using ion exchange resins |
US6800668B1 (en) * | 2001-01-19 | 2004-10-05 | Intellipharmaceutics Corp. | Syntactic deformable foam compositions and methods for making |
US6767913B2 (en) * | 2001-12-18 | 2004-07-27 | Teva Pharmaceutical Industries Ltd. | Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms |
US6800759B2 (en) * | 2002-08-02 | 2004-10-05 | Teva Pharmaceutical Industries Ltd. | Racemization and enantiomer separation of clopidogrel |
CZ297472B6 (en) | 2002-08-27 | 2006-12-13 | Zentiva, A.S. | Process for preparing crystalline form I of clopidogrel hydrogen sulfate |
ITMI20022228A1 (en) * | 2002-10-21 | 2004-04-22 | Dinamite Dipharma S P A | CLOPIDOGREL SALTS WITH ALCHYL-SULPHURIC ACIDS. |
DE10305984A1 (en) * | 2003-02-13 | 2004-09-02 | Helm Ag | Salts of organic acids with clopidogrel and their use in the manufacture of pharmaceutical formulations |
US20050059696A1 (en) * | 2003-05-08 | 2005-03-17 | Dr. Reddy's Laboratories Limited | Process for the recovery of S -(+)-methyl- (2-chlorophenyl)- (6,7-dihydro- 4H-thieno [3,2-c] pyrid-5-yl) acetate hydrogen sulfate (clopidogrel bisulfate) from its (R) and mixture of (R) and (S)- isomers |
US8029822B2 (en) * | 2003-05-22 | 2011-10-04 | Osmotica Kereskedelmi és Seolgáltató KFT | Rupturing controlled release device having a preformed passageway |
US20050036977A1 (en) * | 2003-08-11 | 2005-02-17 | Dilip Gole | Taste-masked resinate and preparation thereof |
US20050112198A1 (en) * | 2003-10-27 | 2005-05-26 | Challapalli Prasad V. | Bupropion formulation for sustained delivery |
US20050181050A1 (en) * | 2004-01-28 | 2005-08-18 | Collegium Pharmaceutical, Inc. | Dosage forms using drug-loaded ion exchange resins |
DE102005060690B4 (en) * | 2005-12-15 | 2008-09-25 | Capsulution Nanoscience Ag | Salts of clopidogrel with polyanions and their use in the preparation of pharmaceutical formulations |
-
2006
- 2006-08-24 AU AU2006292946A patent/AU2006292946B2/en not_active Ceased
- 2006-08-24 CA CA2618187A patent/CA2618187C/en not_active Expired - Fee Related
- 2006-08-24 EP EP06783733A patent/EP1926736A4/en not_active Withdrawn
- 2006-08-24 CN CN2006800320268A patent/CN101253179B/en not_active Expired - Fee Related
- 2006-08-24 WO PCT/KR2006/003346 patent/WO2007035028A1/en active Application Filing
- 2006-08-24 US US12/065,104 patent/US20080226579A1/en not_active Abandoned
- 2006-08-24 JP JP2008528932A patent/JP2009507014A/en active Pending
- 2006-08-24 KR KR1020060080339A patent/KR100736024B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997029753A1 (en) * | 1996-02-19 | 1997-08-21 | Sanofi | New associations of active principles containing clopidogrel and an antithrombotic agent |
EP1087976A1 (en) * | 1998-06-15 | 2001-04-04 | Sanofi-Synthelabo | Polymorphic clopidogrel hydrogenesulphate form |
WO2000066130A1 (en) * | 1999-04-30 | 2000-11-09 | Sanofi-Synthelabo | Pharmaceutical composition in unit form containing acetylsalcylic acid and clopidogrel hydrogenosulphate |
US20030032618A1 (en) * | 1999-12-01 | 2003-02-13 | John Dixon | Pharmaceutical combinations |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009120182A2 (en) * | 2007-12-20 | 2009-10-01 | Eastman Chemical Company | Sulfo-polymer powder and sulfo-polymer powder blends with carriers and/or actives |
WO2009120182A3 (en) * | 2007-12-20 | 2010-10-14 | Eastman Chemical Company | Sulfo-polymer powder and sulfo-polymer powder blends with carriers and/or actives |
EP2377520A1 (en) * | 2010-03-24 | 2011-10-19 | Ratiopharm GmbH | Pharmaceutical compound of prasugrel |
CN111060625A (en) * | 2019-12-31 | 2020-04-24 | 北京鑫开元医药科技有限公司 | Detection method of 2- (thiophene-2-yl) ethyl p-toluenesulfonate and isomer thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2009507014A (en) | 2009-02-19 |
AU2006292946A1 (en) | 2007-03-29 |
CA2618187C (en) | 2011-06-21 |
EP1926736A1 (en) | 2008-06-04 |
KR20070033252A (en) | 2007-03-26 |
CN101253179A (en) | 2008-08-27 |
US20080226579A1 (en) | 2008-09-18 |
AU2006292946B2 (en) | 2009-12-10 |
KR100736024B1 (en) | 2007-07-06 |
CN101253179B (en) | 2010-12-29 |
CA2618187A1 (en) | 2007-03-29 |
EP1926736A4 (en) | 2010-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001256227B2 (en) | Hydrophilic molecular disperse solutions of carvedilol | |
CA2618187C (en) | Novel resinate complex of s-clopidogrel and production method thereof | |
ZA200509155B (en) | Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same | |
CA2160423A1 (en) | Salts of nefazodone having improved dissolution rates | |
US8614315B2 (en) | Cefdinir and cefixime formulations and uses thereof | |
KR100525275B1 (en) | Solid Dispersion Containing Sialic Acid Derivative | |
JP2007517864A (en) | Cefuroxime axetil granules and method for producing the same | |
EP0804168A1 (en) | Taste masked composition containing a drug/polymer complex | |
SK302003A3 (en) | Stable gabapentin having pH within a controlled range | |
KR102276281B1 (en) | Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine | |
CZ20014379A3 (en) | Composition for masking taste and process for preparing thereof | |
KR20080055356A (en) | Inclusion complex of clopidogrel and beta-cyclodextrin | |
KR20040104020A (en) | A new rebamipide lysinate, rebamipide argininate and pharmaceutical preparation containing the same as active substance | |
PL202027B1 (en) | Masking of taste of oral, liquid quinolone preparations by using ion-exchange resins | |
KR100479367B1 (en) | Composition comprising itraconazole for oral administration | |
KR100523242B1 (en) | A tablet composition containing ibuprofen | |
KR100910306B1 (en) | Wetgranulation composition containg Sibutramine free base | |
EP1355632B1 (en) | Amlodipine free base | |
KR100759607B1 (en) | Cefuroxime axetil granule and process for the preparation thereof | |
KR100700721B1 (en) | Tablets of S+-Ibuprofen having improved stability and dissolution rate | |
EP1640374A1 (en) | Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same | |
KR20060126154A (en) | Solid dispersion of lercanidipine and manufacturing method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680032026.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2008528932 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2618187 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006292946 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006783733 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12065104 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2006292946 Country of ref document: AU Date of ref document: 20060824 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |